{"trials": {"1": {"nct_id": "NCT05945147", "drug_name": "Ketamine", "intervention_type": "DRUG", "drug_description": "An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Lack of funding", "title": "Ketamine and Midazolam Infusions for CRPS: Feasibility Study", "start_date": "2099-01-01", "completion_date": "2099-05-31", "sponsor": "Stanford University", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.743782", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T00:46:50.475971", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL5095435", "pref_name": "FAZIRSIRAN", "targets": [{"chembl_id": null, "uniprot_id": "P08912", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P30939", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P08173", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P28566", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P28221", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM5", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM5", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM5", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM5", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM5", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM5", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM5", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB4", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB5", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB2", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "HTR1F", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAI1", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "GNB5", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "GNB2", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "HTR1F", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "GNB1", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "GNAI1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "GNG11", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG11", "protein_b": "HTR1F", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNG11", "protein_b": "GNB5", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "GNG11", "protein_b": "GNB2", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "GNG11", "protein_b": "GNG2", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "GNG11", "protein_b": "GNAI1", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "GNG11", "protein_b": "GNB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNB5", "protein_b": "GNB2", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "GNB5", "protein_b": "HTR1F", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "GNB5", "protein_b": "GNB1", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "GNB5", "protein_b": "GNAI1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB5", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB5", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "HTR1F", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNB1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNAI1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HTR1F", "protein_b": "EDN3", "combined_score": 0.727, "interaction_type": "physical"}, {"protein_a": "HTR1F", "protein_b": "GNG7", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "HTR1F", "protein_b": "GNG2", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "HTR1F", "protein_b": "GNAI1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "HTR1F", "protein_b": "GNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG7", "protein_b": "GNAI1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "CHRM4", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNG2", "combined_score": 0.705, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNAI2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNAI1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CHRM4", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG12", "combined_score": 0.877, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG10", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CHRM4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNG10", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNAI1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM4", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "CHRM4", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "GNAI1", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "CHRM4", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CHRM4", "protein_b": "GNAI1", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "CHRM4", "protein_b": "KNG1", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "GNB5", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "GNB2", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "HTR1E", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "HTR1D", "combined_score": 0.744, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "HTR1B", "combined_score": 0.744, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "GNB1", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "GNAI1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB4", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB5", "protein_b": "GNB2", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "GNB5", "protein_b": "HTR1E", "combined_score": 0.74, "interaction_type": "physical"}, {"protein_a": "GNB5", "protein_b": "HTR1D", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "GNB5", "protein_b": "HTR1B", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "GNB5", "protein_b": "GNB1", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "GNB5", "protein_b": "GNAI1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB5", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB5", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "HTR1D", "combined_score": 0.744, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "HTR1B", "combined_score": 0.744, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "HTR1E", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNB1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNAI1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HTR1E", "protein_b": "HTR1D", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "HTR1E", "protein_b": "HTR1B", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "HTR1E", "protein_b": "HTR3A", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "HTR1E", "protein_b": "GNG7", "combined_score": 0.818, "interaction_type": "physical"}, {"protein_a": "HTR1E", "protein_b": "GNG2", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "HTR1E", "protein_b": "GNAI1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "HTR1E", "protein_b": "GNB1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "HTR1D", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "HTR1B", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HTR3A", "protein_b": "HTR1B", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "HTR3A", "protein_b": "HTR1D", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "HTR1B", "protein_b": "GNG7", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "HTR1B", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "HTR1B", "protein_b": "HTR1D", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "HTR1B", "protein_b": "GNB1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "HTR1D", "protein_b": "GNG7", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "HTR1D", "protein_b": "GNAI1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "HTR1D", "protein_b": "GNB1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG7", "protein_b": "GNAI1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "HTR1D", "combined_score": 0.764, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "HTR1B", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAI1", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "MAOB", "combined_score": 0.756, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR1D", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR1B", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "SLC6A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR3A", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "MAOB", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1B", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "HTR1D", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "HTR1B", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HTR3A", "protein_b": "HTR1B", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "HTR3A", "protein_b": "HTR1D", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "HTR1B", "protein_b": "GNG7", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "HTR1B", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "HTR1B", "protein_b": "MAOB", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "HTR1B", "protein_b": "HTR1D", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "HTR1B", "protein_b": "GNB1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "HTR1D", "protein_b": "MAOB", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "HTR1D", "protein_b": "GNG7", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "HTR1D", "protein_b": "GNAI1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "HTR1D", "protein_b": "GNB1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG7", "protein_b": "GNAI1", "combined_score": 0.973, "interaction_type": "physical"}], "network_features": {"avg_degree": 11.47, "clustering_coefficient": 5.73}}, "failure_enrichment": {"aact_description": "Subanesthetic ketamine infusions are a potentially impactful treatment for chronic refractory pain, but the acute psychoactive effects of ketamine complicate successful masking in randomized trials. Multi-day ketamine infusions have produced long-lasting, but not permanent, remission of symptoms in complex regional pain syndrome (CRPS), a chronic and often debilitating neuropathic pain condition that can affect one or more limbs. In this feasibility study, 4 adults with CRPS will be randomized to receive either ketamine and midazolam or midazolam-only, infused over 5 days in an outpatient setting. The objectives of this feasibility study are:\n\n1. Assess whether the recruitment and retention rate observed in this feasibility study can support a larger clinical trial.\n2. Evaluate whether participants can adhere to study procedures.\n3. Determine whether midazolam, when given alone as an intravenous (IV) infusion, can be used as an active placebo that is well-tolerated, practical, and believable compared to a ketamine plus midazolam infusion.\n4. Gather preliminary data on clinically-relevant outcomes for CRPS.", "aact_documents": [], "pubmed_results": [{"pmid": "41221496", "title": "Efficacy and Safety of Esketamine-Lidocaine for Anesthesia Induction in Elderly Patients Undergoing Elective Surgery: A Randomized Controlled Trial.", "authors": [{"name": "Xu J", "authtype": "Author", "clusterid": ""}, {"name": "Yuan M", "authtype": "Author", "clusterid": ""}, {"name": "Zhou T", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41217338", "title": "The hemodynamic effects of esketamine-based opioid-free anesthesia in laparoscopic hepatectomy: a randomized clinical trial.", "authors": [{"name": "Yao Y", "authtype": "Author", "clusterid": ""}, {"name": "Yang S", "authtype": "Author", "clusterid": ""}, {"name": "Xu Y", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41209744", "title": "The Analgesic Effect of Low-Dose S(+)-Ketamine in Knee Joint Replacement: A Randomized Controlled Trial.", "authors": [{"name": "Deng SY", "authtype": "Author", "clusterid": ""}, {"name": "Song X", "authtype": "Author", "clusterid": ""}, {"name": "Chen LN", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41209150", "title": "Low-Dose Esketamine Plus Dexmedetomidine in Patient-Controlled Intravenous Analgesia Improves Post-Cesarean Sleep Quality: A Double-Blind Randomized Trial.", "authors": [{"name": "Zhang L", "authtype": "Author", "clusterid": ""}, {"name": "He Y", "authtype": "Author", "clusterid": ""}, {"name": "Chen L", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41198736", "title": "Opioid-free anesthesia with quadratus lumborum block and Esketamine enhances postoperative recovery in laparoscopic colon cancer surgery: A randomized controlled trial.", "authors": [{"name": "Cheng CX", "authtype": "Author", "clusterid": ""}, {"name": "Wang K", "authtype": "Author", "clusterid": ""}, {"name": "Jiang YX", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).", "detailed_description": "Subanesthetic ketamine infusions are a potentially impactful treatment for chronic refractory pain, but the acute psychoactive effects of ketamine complicate successful masking in randomized trials. Multi-day ketamine infusions have produced long-lasting, but not permanent, remission of symptoms in complex regional pain syndrome (CRPS), a chronic and often debilitating neuropathic pain condition that can affect one or more limbs. In this feasibility study, 4 adults with CRPS will be randomized to receive either ketamine and midazolam or midazolam-only, infused over 5 days in an outpatient setting. The objectives of this feasibility study are:\n\n1. Assess whether the recruitment and retention rate observed in this feasibility study can support a larger clinical trial.\n2. Evaluate whether participants can adhere to study procedures.\n3. Determine whether midazolam, when given alone as an intravenous (IV) infusion, can be used as an active placebo that is well-tolerated, practical, and believable compared to a ketamine plus midazolam infusion.\n4. Gather preliminary data on clinically-relevant outcomes for CRPS.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Ketamine and Midazolam", "type": "EXPERIMENTAL", "description": "Participants will receive intravenous infusions of ketamine and midazolam for 4 hours each day, over 5 consecutive days, in an outpatient setting.", "intervention_names": ["Drug: Ketamine", "Drug: Midazolam"]}, {"label": "Midazolam and Saline", "type": "PLACEBO_COMPARATOR", "description": "Participants will receive intravenous infusions of midazolam and normal saline for 4 hours each day, over 5 consecutive days, in an outpatient setting.", "intervention_names": ["Drug: Midazolam", "Drug: Normal Saline"]}], "interventions": [{"type": "DRUG", "name": "Ketamine", "description": "An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Ketamine and Midazolam"]}, {"type": "DRUG", "name": "Midazolam", "description": "A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Ketamine and Midazolam", "Midazolam and Saline"]}, {"type": "DRUG", "name": "Normal Saline", "description": "An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Midazolam and Saline"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Stanford University+NCT05945147+terminated", "https://www.google.com/search?q=Stanford University+Ketamine+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": false, "search_query": "FDA warning letters or clinical holds for Ketamine by Stanford University. Include specific dates, reasons, and safety issues cited.", "error": "API error: 400"}, "sec_filings": {"found": false, "search_query": "SEC EDGAR 8-K filings by Stanford University mentioning clinical trial NCT05945147 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "search_params": {"company": "Stanford University", "nct_id": "NCT05945147", "start_date": "2099-01-01"}, "error": "API error: 400"}, "company_disclosures": {"found": false, "search_query": "Company press releases, investor presentations, or public statements by Stanford University about clinical trial NCT05945147 for Ketamine. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "search_params": {"company": "Stanford University", "nct_id": "NCT05945147", "drug_name": "Ketamine"}, "error": "API error: 400"}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "Based on the information provided, the trial was withdrawn due to lack of funding, which is an administrative issue rather than safety or efficacy concerns. The detailed description does not mention any safety issues or lack of efficacy, and the official reason for withdrawal is explicitly stated as \"Lack of funding.\" Therefore, this trial was terminated for administrative reasons, specifically due to a lack of funding to continue the study.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T00:46:50.475361", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1203}}, "2": {"nct_id": "NCT05945147", "drug_name": "Midazolam", "intervention_type": "DRUG", "drug_description": "A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Lack of funding", "title": "Ketamine and Midazolam Infusions for CRPS: Feasibility Study", "start_date": "2099-01-01", "completion_date": "2099-05-31", "sponsor": "Stanford University", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.744511", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T00:46:50.480571", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL2170375", "pref_name": null, "targets": [{"chembl_id": null, "uniprot_id": "P02763", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q8N1C3", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q9UN88", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "O00591", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P78334", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "ORM1", "protein_b": "SPTLC3", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "SERPINA3", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "AMBP", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "CP", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "AHSG", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "SPTLC1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "HP", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "SERPINA1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "ALB", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "ORM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SPTLC1", "protein_b": "SPTLC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "AHSG", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "SERPINA3", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "ORM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "ALB", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "SERPINA1", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "HP", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "SERPINA1", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "HP", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "ORM2", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "AHSG", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "ALB", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "SERPINA3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "HP", "combined_score": 0.882, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "ORM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "SERPINA1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "ALB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "SERPINA3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "HP", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "SERPINA1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "ORM2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "HP", "protein_b": "SERPINA3", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "HP", "protein_b": "ORM2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "HP", "protein_b": "SERPINA1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "ORM2", "protein_b": "SERPINA3", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "ORM2", "protein_b": "SERPINA1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "GABARAP", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "GABRG1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "NSF", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "PLCL1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "HAP1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "GABRB1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "TRAK2", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "GABRG2", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "GABRA1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "GABRA1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "GABARAPL1", "combined_score": 0.818, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "GABARAP", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "GABRG2", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "GABRB1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "HAP1", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "TRAK2", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "NSF", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "PLCL1", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "GABARAPL1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "GABARAP", "combined_score": 0.818, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "GABRG2", "combined_score": 0.87, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "PLCL1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "TRAK2", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "NSF", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "HAP1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "GABRA1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "GABARAP", "protein_b": "GABRA1", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "GABARAP", "protein_b": "GABRG2", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "GABARAP", "protein_b": "GABARAPL1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "TRAK2", "protein_b": "GABRA1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "HAP1", "protein_b": "GABRA1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "NSF", "protein_b": "GABRA1", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "GABRA1", "protein_b": "GABARAPL1", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "GABRA1", "protein_b": "PLCL1", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GABRA1", "protein_b": "GABRG2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRQ", "combined_score": 0.754, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRG3", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRA3", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRG2", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRE", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRA1", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "TRAK2", "protein_b": "GABRQ", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "TRAK2", "protein_b": "GABRG3", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "TRAK2", "protein_b": "GABRE", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TRAK2", "protein_b": "GABRA3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "TRAK2", "protein_b": "GABRA1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "HAP1", "protein_b": "GABRG3", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "HAP1", "protein_b": "GABRA3", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "HAP1", "protein_b": "GABRQ", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "HAP1", "protein_b": "GABRE", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "HAP1", "protein_b": "GABRA1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "GABRA3", "protein_b": "GABRG3", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "GABRA3", "protein_b": "GABRG2", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "GABRA3", "protein_b": "GABRQ", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "GABRA3", "protein_b": "PLCL1", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GABRA3", "protein_b": "NSF", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GABRE", "protein_b": "GABRQ", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "GABRE", "protein_b": "GABRA1", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "GABRE", "protein_b": "NSF", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GABRE", "protein_b": "PLCL1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "NSF", "protein_b": "GABRQ", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "NSF", "protein_b": "GABRG3", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "NSF", "protein_b": "GABRA1", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "GABRA1", "protein_b": "GABRG3", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "GABRA1", "protein_b": "GABRQ", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "GABRA1", "protein_b": "PLCL1", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GABRA1", "protein_b": "GABRG2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PLCL1", "protein_b": "GABRQ", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PLCL1", "protein_b": "GABRG3", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GABRG2", "protein_b": "GABRG3", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "GABRG2", "protein_b": "GABRQ", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "GABRQ", "protein_b": "GABRG3", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRP", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRA6", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRE", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRA1", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "GABRA6", "protein_b": "GABRP", "combined_score": 0.707, "interaction_type": "physical"}, {"protein_a": "GABRA6", "protein_b": "GABRA1", "combined_score": 0.818, "interaction_type": "physical"}, {"protein_a": "GABRA6", "protein_b": "TRAK2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GABRA6", "protein_b": "HAP1", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "GABRA6", "protein_b": "NSF", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GABRA6", "protein_b": "PLCL1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "TRAK2", "protein_b": "GABRP", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "TRAK2", "protein_b": "GABRE", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TRAK2", "protein_b": "GABRA1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "HAP1", "protein_b": "GABRP", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "HAP1", "protein_b": "GABRE", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "HAP1", "protein_b": "GABRA1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "GABRE", "protein_b": "GABRP", "combined_score": 0.705, "interaction_type": "physical"}, {"protein_a": "GABRE", "protein_b": "GABRA1", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "GABRE", "protein_b": "NSF", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GABRE", "protein_b": "PLCL1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "NSF", "protein_b": "GABRP", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NSF", "protein_b": "GABRA1", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "GABRA1", "protein_b": "GABRP", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "GABRA1", "protein_b": "PLCL1", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PLCL1", "protein_b": "GABRP", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRQ", "combined_score": 0.754, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRE", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRB1", "combined_score": 0.884, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRA2", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRA1", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "GABBR2", "protein_b": "GABRB3", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "GABRE", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "PLCL1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "TRAK2", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "NSF", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "GABRA2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "HAP1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "GABRB3", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "GABRA1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "GABRB3", "protein_b": "GABRE", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "GABRB3", "protein_b": "GABRA2", "combined_score": 0.829, "interaction_type": "physical"}, {"protein_a": "GABRB3", "protein_b": "PLCL1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "GABRB3", "protein_b": "TRAK2", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GABRB3", "protein_b": "HAP1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GABRB3", "protein_b": "NSF", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GABRB3", "protein_b": "GABRA1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "TRAK2", "protein_b": "GABRQ", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "TRAK2", "protein_b": "GABRE", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TRAK2", "protein_b": "GABRA1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "HAP1", "protein_b": "GABRQ", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "HAP1", "protein_b": "GABRE", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "HAP1", "protein_b": "GABRA1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "GABRE", "protein_b": "GABRQ", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "GABRE", "protein_b": "GABRA1", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "GABRE", "protein_b": "GABRA2", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GABRE", "protein_b": "NSF", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GABRE", "protein_b": "PLCL1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "NSF", "protein_b": "GABRQ", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "NSF", "protein_b": "GABRA1", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "GABRA1", "protein_b": "GABRA2", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "GABRA1", "protein_b": "GABRQ", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "GABRA1", "protein_b": "PLCL1", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PLCL1", "protein_b": "GABRQ", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GABRA2", "protein_b": "GABRQ", "combined_score": 0.719, "interaction_type": "physical"}], "network_features": {"avg_degree": 11.1, "clustering_coefficient": 5.55}}, "failure_enrichment": {"aact_description": "Subanesthetic ketamine infusions are a potentially impactful treatment for chronic refractory pain, but the acute psychoactive effects of ketamine complicate successful masking in randomized trials. Multi-day ketamine infusions have produced long-lasting, but not permanent, remission of symptoms in complex regional pain syndrome (CRPS), a chronic and often debilitating neuropathic pain condition that can affect one or more limbs. In this feasibility study, 4 adults with CRPS will be randomized to receive either ketamine and midazolam or midazolam-only, infused over 5 days in an outpatient setting. The objectives of this feasibility study are:\n\n1. Assess whether the recruitment and retention rate observed in this feasibility study can support a larger clinical trial.\n2. Evaluate whether participants can adhere to study procedures.\n3. Determine whether midazolam, when given alone as an intravenous (IV) infusion, can be used as an active placebo that is well-tolerated, practical, and believable compared to a ketamine plus midazolam infusion.\n4. Gather preliminary data on clinically-relevant outcomes for CRPS.", "aact_documents": [], "pubmed_results": [{"pmid": "41222450", "title": "Characterization of Drug-Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS-CoV-2, in Healthy Participants.", "authors": [{"name": "Chang J", "authtype": "Author", "clusterid": ""}, {"name": "Kim A", "authtype": "Author", "clusterid": ""}, {"name": "Humeniuk R", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41164404", "title": "Intranasal Dexmedetomidine with Propofol Provides Superior Sedation for Pediatric Contrast-Enhanced CT: A Randomized Controlled Trial.", "authors": [{"name": "Zhang SJ", "authtype": "Author", "clusterid": ""}, {"name": "Weng YJ", "authtype": "Author", "clusterid": ""}, {"name": "Lei Q", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41150706", "title": "Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin Lymphoma.", "authors": [{"name": "Tachibana M", "authtype": "Author", "clusterid": ""}, {"name": "Horwitz S", "authtype": "Author", "clusterid": ""}, {"name": "Jacobsen E", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41123905", "title": "Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression: The KARMA-Dep 2 Randomized Clinical Trial.", "authors": [{"name": "Jelovac A", "authtype": "Author", "clusterid": ""}, {"name": "McCaffrey C", "authtype": "Author", "clusterid": ""}, {"name": "Terao M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41121399", "title": "Esketamine versus sufentanil as analgesics for sedation during painless gastrointestinal endoscopy: a double-blinded randomized controlled trial.", "authors": [{"name": "Li TT", "authtype": "Author", "clusterid": ""}, {"name": "He XL", "authtype": "Author", "clusterid": ""}, {"name": "Tang HL", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).", "detailed_description": "Subanesthetic ketamine infusions are a potentially impactful treatment for chronic refractory pain, but the acute psychoactive effects of ketamine complicate successful masking in randomized trials. Multi-day ketamine infusions have produced long-lasting, but not permanent, remission of symptoms in complex regional pain syndrome (CRPS), a chronic and often debilitating neuropathic pain condition that can affect one or more limbs. In this feasibility study, 4 adults with CRPS will be randomized to receive either ketamine and midazolam or midazolam-only, infused over 5 days in an outpatient setting. The objectives of this feasibility study are:\n\n1. Assess whether the recruitment and retention rate observed in this feasibility study can support a larger clinical trial.\n2. Evaluate whether participants can adhere to study procedures.\n3. Determine whether midazolam, when given alone as an intravenous (IV) infusion, can be used as an active placebo that is well-tolerated, practical, and believable compared to a ketamine plus midazolam infusion.\n4. Gather preliminary data on clinically-relevant outcomes for CRPS.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Ketamine and Midazolam", "type": "EXPERIMENTAL", "description": "Participants will receive intravenous infusions of ketamine and midazolam for 4 hours each day, over 5 consecutive days, in an outpatient setting.", "intervention_names": ["Drug: Ketamine", "Drug: Midazolam"]}, {"label": "Midazolam and Saline", "type": "PLACEBO_COMPARATOR", "description": "Participants will receive intravenous infusions of midazolam and normal saline for 4 hours each day, over 5 consecutive days, in an outpatient setting.", "intervention_names": ["Drug: Midazolam", "Drug: Normal Saline"]}], "interventions": [{"type": "DRUG", "name": "Ketamine", "description": "An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Ketamine and Midazolam"]}, {"type": "DRUG", "name": "Midazolam", "description": "A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Ketamine and Midazolam", "Midazolam and Saline"]}, {"type": "DRUG", "name": "Normal Saline", "description": "An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Midazolam and Saline"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Stanford University+NCT05945147+terminated", "https://www.google.com/search?q=Stanford University+Midazolam+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": false, "search_query": "FDA warning letters or clinical holds for Midazolam by Stanford University. Include specific dates, reasons, and safety issues cited.", "error": "API error: 400"}, "sec_filings": {"found": false, "search_query": "SEC EDGAR 8-K filings by Stanford University mentioning clinical trial NCT05945147 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "search_params": {"company": "Stanford University", "nct_id": "NCT05945147", "start_date": "2099-01-01"}, "error": "API error: 400"}, "company_disclosures": {"found": false, "search_query": "Company press releases, investor presentations, or public statements by Stanford University about clinical trial NCT05945147 for Midazolam. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "search_params": {"company": "Stanford University", "nct_id": "NCT05945147", "drug_name": "Midazolam"}, "error": "API error: 400"}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "Based on the information provided, the trial was withdrawn due to lack of funding, which is an administrative issue rather than safety or efficacy concerns. The detailed description does not mention any safety issues or lack of efficacy, and the official reason for withdrawal is explicitly stated as \"Lack of funding.\" Therefore, this trial was terminated for administrative reasons, specifically due to a lack of funding to continue the study.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T00:46:50.475361", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1203}}, "3": {"nct_id": "NCT05945147", "drug_name": "Normal Saline", "intervention_type": "DRUG", "drug_description": "An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Lack of funding", "title": "Ketamine and Midazolam Infusions for CRPS: Feasibility Study", "start_date": "2099-01-01", "completion_date": "2099-05-31", "sponsor": "Stanford University", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.744837", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T00:46:50.482427", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1200574", "pref_name": "SODIUM CHLORIDE", "targets": [{"chembl_id": null, "uniprot_id": "Q940H6", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q0JNS6", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q6ZI01", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q40359", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "sodium chloride", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 4, "interactions": [], "network_features": {"avg_degree": 0, "clustering_coefficient": 0}}, "failure_enrichment": {"aact_description": "Subanesthetic ketamine infusions are a potentially impactful treatment for chronic refractory pain, but the acute psychoactive effects of ketamine complicate successful masking in randomized trials. Multi-day ketamine infusions have produced long-lasting, but not permanent, remission of symptoms in complex regional pain syndrome (CRPS), a chronic and often debilitating neuropathic pain condition that can affect one or more limbs. In this feasibility study, 4 adults with CRPS will be randomized to receive either ketamine and midazolam or midazolam-only, infused over 5 days in an outpatient setting. The objectives of this feasibility study are:\n\n1. Assess whether the recruitment and retention rate observed in this feasibility study can support a larger clinical trial.\n2. Evaluate whether participants can adhere to study procedures.\n3. Determine whether midazolam, when given alone as an intravenous (IV) infusion, can be used as an active placebo that is well-tolerated, practical, and believable compared to a ketamine plus midazolam infusion.\n4. Gather preliminary data on clinically-relevant outcomes for CRPS.", "aact_documents": [], "pubmed_results": [{"pmid": "41221568", "title": "Efficacy and safety of tranexamic acid nebulization to control bleeding of hemoptysis: The TXA-NEB randomized controlled clinical trial.", "authors": [{"name": "Agrawal A", "authtype": "Author", "clusterid": ""}, {"name": "Dhibar DP", "authtype": "Author", "clusterid": ""}, {"name": "Prakash A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41221567", "title": "Effect of dexmedetomidine combined with ropivacaine in ultrasound-guided paravertebral nerve block for acute herpes zoster neuralgia patients.", "authors": [{"name": "Liu C", "authtype": "Author", "clusterid": ""}, {"name": "Wang Y", "authtype": "Author", "clusterid": ""}, {"name": "Wang P", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41214223", "title": "Nasal allergen challenge with dissolved birch tree pollen tablets.", "authors": [{"name": "Paziou E", "authtype": "Author", "clusterid": ""}, {"name": "Ali KJ", "authtype": "Author", "clusterid": ""}, {"name": "Geor\u00e9n SK", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41200477", "title": "Efficacy of Intravenous Butorphanol for Preventing Epidural-Related Maternal Fever (ERMF) During Epidural Labor Analgesia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.", "authors": [{"name": "Zhang Y", "authtype": "Author", "clusterid": ""}, {"name": "Chen X", "authtype": "Author", "clusterid": ""}, {"name": "Xu S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41198897", "title": "Effects of chlorhexidine and a polyherbal mouthwash on the oral microbiome and user satisfaction: a randomized controlled trial.", "authors": [{"name": "Wattanawongwan W", "authtype": "Author", "clusterid": ""}, {"name": "Krasaesin A", "authtype": "Author", "clusterid": ""}, {"name": "Khieota T", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).", "detailed_description": "Subanesthetic ketamine infusions are a potentially impactful treatment for chronic refractory pain, but the acute psychoactive effects of ketamine complicate successful masking in randomized trials. Multi-day ketamine infusions have produced long-lasting, but not permanent, remission of symptoms in complex regional pain syndrome (CRPS), a chronic and often debilitating neuropathic pain condition that can affect one or more limbs. In this feasibility study, 4 adults with CRPS will be randomized to receive either ketamine and midazolam or midazolam-only, infused over 5 days in an outpatient setting. The objectives of this feasibility study are:\n\n1. Assess whether the recruitment and retention rate observed in this feasibility study can support a larger clinical trial.\n2. Evaluate whether participants can adhere to study procedures.\n3. Determine whether midazolam, when given alone as an intravenous (IV) infusion, can be used as an active placebo that is well-tolerated, practical, and believable compared to a ketamine plus midazolam infusion.\n4. Gather preliminary data on clinically-relevant outcomes for CRPS.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Ketamine and Midazolam", "type": "EXPERIMENTAL", "description": "Participants will receive intravenous infusions of ketamine and midazolam for 4 hours each day, over 5 consecutive days, in an outpatient setting.", "intervention_names": ["Drug: Ketamine", "Drug: Midazolam"]}, {"label": "Midazolam and Saline", "type": "PLACEBO_COMPARATOR", "description": "Participants will receive intravenous infusions of midazolam and normal saline for 4 hours each day, over 5 consecutive days, in an outpatient setting.", "intervention_names": ["Drug: Midazolam", "Drug: Normal Saline"]}], "interventions": [{"type": "DRUG", "name": "Ketamine", "description": "An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Ketamine and Midazolam"]}, {"type": "DRUG", "name": "Midazolam", "description": "A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Ketamine and Midazolam", "Midazolam and Saline"]}, {"type": "DRUG", "name": "Normal Saline", "description": "An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Midazolam and Saline"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Stanford University+NCT05945147+terminated", "https://www.google.com/search?q=Stanford University+Normal Saline+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": false, "search_query": "FDA warning letters or clinical holds for Normal Saline by Stanford University. Include specific dates, reasons, and safety issues cited.", "error": "API error: 400"}, "sec_filings": {"found": false, "search_query": "SEC EDGAR 8-K filings by Stanford University mentioning clinical trial NCT05945147 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "search_params": {"company": "Stanford University", "nct_id": "NCT05945147", "start_date": "2099-01-01"}, "error": "API error: 400"}, "company_disclosures": {"found": false, "search_query": "Company press releases, investor presentations, or public statements by Stanford University about clinical trial NCT05945147 for Normal Saline. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "search_params": {"company": "Stanford University", "nct_id": "NCT05945147", "drug_name": "Normal Saline"}, "error": "API error: 400"}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "Based on the information provided, the trial was withdrawn due to lack of funding, which is an administrative issue rather than safety or efficacy concerns. The detailed description does not mention any safety issues or lack of efficacy, and the official reason for withdrawal is explicitly stated as \"Lack of funding.\" Therefore, this trial was terminated for administrative reasons, specifically due to a lack of funding to continue the study.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T00:46:50.475361", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1203}}, "16": {"nct_id": "NCT06940570", "drug_name": "PCA Alone (SOC)", "intervention_type": "DRUG", "drug_description": "PCA Alone (Control) arm. PCA opioid will include morphine OR hydromorphone (if patient has a sensitivity or is unable to tolerate or allergic to morphine).", "phase": "PHASE3", "overall_status": "SUSPENDED", "why_stopped": "Study is closed with the IRB due to no funding. May resume once funding is obtained.", "title": "Methadone as an Alternative Treatment for Children Underdoing HSCT", "start_date": "2028-01-01", "completion_date": "2029-08-01", "sponsor": "University of Texas Southwestern Medical Center", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.749086", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T00:46:52.321230", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1590048", "pref_name": null, "targets": [], "has_uniprot_targets": false, "search_name": "PCA Alone (SOC)"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "Given high reports of pain while despite receiving PCA during transplant, our current management of mucositis induced pain is suboptimal. In a study of children receiving transplantation, pain was a main concern for this cohort during and after transplantation. The investigators propose to conduct this study to determine if methadone used as a primary analgesic in patients with mucositis can improve the current standard of care which will be demonstrated by improved pain scores, maintenance of functionality, and recovery during and following HSCT. This study will be a single blind randomized controlled design. Patients will be randomly assigned by permuted block randomization in groups of eight. Patient will be randomly assigned to receive either basal/PCA of one opioid (control) in the first arm OR PCA plus methadone where methadone will be used as basal long-acting medication (experimental).\n\nStudy subjects will be children who are undergoing an autologous or allogeneic stem cell transplant receiving a myeloablative regimen and meet all inclusion criteria. This unique population is being studied as it is a controlled setting where the PI can anticipate pain in \\>90% of the patients following ablation, the number of patients who experience mucositis after receiving ablative conditioning. The study will only be conducted in the inpatient stem cell transplant setting and no follow up should be necessary when these subjects are discharged from the hospital after transplant.\n\nThe following goals of the study are as follows:\n\n1. Will the concomitant administration of intravenous administered methadone with on demand opioid PCA improve pain score numbers in the PCA/methadone arm (experimental) in comparison to a continuous infusion PCA with demand opioid arm (control, standard of care)?\n2. Will the administration of methadone with increased individualized titration result in a reduction of 25% in total morphine milligram equivalents (MME) in experimental versus control arm?\n3. Will the methadone experimental arm increase functionality during transplantation period?\n4. Will those receiving methadone have reduced TPN days during hospital stay as compared to control arm?\n5. Will the child resumes oral intake more rapidly compared to control arm?\n6. The investigators also want to describe adverse events and incidence associated with methadone when administered in combination with morphine or hydromorphone, specifically QTc prolongation that has been documented with study medication.", "aact_documents": [], "pubmed_results": [{"pmid": "36879271", "title": "DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy na\u00efve men-study protocol for a randomized trial.", "authors": [{"name": "Krausewitz P", "authtype": "Author", "clusterid": ""}, {"name": "Bundschuh RA", "authtype": "Author", "clusterid": ""}, {"name": "Gaertner FC", "authtype": "Author", "clusterid": ""}]}, {"pmid": "33491604", "title": "Adding Ritualized Chanting to the Palliative Care of Cancer Patients at the End of Life: A Randomized Controlled Trial.", "authors": [{"name": "Maungtoug N", "authtype": "Author", "clusterid": ""}, {"name": "Othaganont P", "authtype": "Author", "clusterid": ""}, {"name": "Liehr P", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "Mucositis is a normal side effect of stem cell transplant which happens as a result of chemotherapy being given prior to a new donor cell infusion (bone marrow transplant). The chemotherapy will kill cancer cells, but good cells, such as those in the mouth, are killed too. The mouth cells going away causes the areas in the mouth to be blistered, irritated, sore, and extremely painful. Pain medication (usually morphine or hydromorphone if allergic to morphine) are given when oral blisters are seen or felt by patient in patient's mouth. However, one pain medication given through a vein in the patient may or may not be effective and providers are often challenged with providing good pain control while waiting for the new donor cells to grow, which will then heal the mouth. This is a period of waiting that is 6-8 weeks.\n\nThe investigators know that methadone, a second pain medication, may decrease pain in a different way than morphine. This is because methadone works in a different way in the brain than morphine. By giving these pain medicines together, the hope of the study is to show decreased pain while waiting for new cells to grow.\n\nThe goal of this clinical trial is to hope to learn whether adding methadone (second pain medication) to the current pain medication which is morphine alone (all patients will receive this pain medication) will help reduce the pain experience of participant. Current treatment of morphine alone is sometimes not entirely effective and so any improvement of pain while waiting for new cells to grow is one of the goals of this study. If methadone is effective in decreasing pain, then patients may benefit in the future from using these two medications up front when getting a transplant.\n\nParticipant in this study between 6-18 years of age and is needing a stem cell transplant for a disease that can potentially be cured by transplantation.\n\nParticipant in this study is receiving chemotherapy and/or radiation conditioning that can cause mucositis. Participants are being asked to participate in this study because participants meet criteria to receive methadone that may or may not reduce pain experience versus just being given morphine alone, which is what all patients are given when the participants have mucositis.\n\nThe main goal of the study is to see if less opioid (pain medication) when methadone is added in comparison to participant who uses PCA only. The investigators also want to learn if patient's overall function is improved if given methadone. Another goal would be to see the number of TPN days the participant received and if the participant who was given methadone began to eat sooner. Other smaller goals include learning about side effects of methadone, and if the hospital stay is less for those who receive the study medication.\n\nThis medication will be given at Children's Medical Center of Dallas while participant is admitted for the stem cell transplant. There is no sponsor that is funding the study and this drug will be given free of charge in exchange for participation in the study", "detailed_description": "Given high reports of pain while despite receiving PCA during transplant, our current management of mucositis induced pain is suboptimal. In a study of children receiving transplantation, pain was a main concern for this cohort during and after transplantation. The investigators propose to conduct this study to determine if methadone used as a primary analgesic in patients with mucositis can improve the current standard of care which will be demonstrated by improved pain scores, maintenance of functionality, and recovery during and following HSCT. This study will be a single blind randomized controlled design. Patients will be randomly assigned by permuted block randomization in groups of eight. Patient will be randomly assigned to receive either basal/PCA of one opioid (control) in the first arm OR PCA plus methadone where methadone will be used as basal long-acting medication (experimental).\n\nStudy subjects will be children who are undergoing an autologous or allogeneic stem cell transplant receiving a myeloablative regimen and meet all inclusion criteria. This unique population is being studied as it is a controlled setting where the PI can anticipate pain in \\>90% of the patients following ablation, the number of patients who experience mucositis after receiving ablative conditioning. The study will only be conducted in the inpatient stem cell transplant setting and no follow up should be necessary when these subjects are discharged from the hospital after transplant.\n\nThe following goals of the study are as follows:\n\n1. Will the concomitant administration of intravenous administered methadone with on demand opioid PCA improve pain score numbers in the PCA/methadone arm (experimental) in comparison to a continuous infusion PCA with demand opioid arm (control, standard of care)?\n2. Will the administration of methadone with increased individualized titration result in a reduction of 25% in total morphine milligram equivalents (MME) in experimental versus control arm?\n3. Will the methadone experimental arm increase functionality during transplantation period?\n4. Will those receiving methadone have reduced TPN days during hospital stay as compared to control arm?\n5. Will the child resumes oral intake more rapidly compared to control arm?\n6. The investigators also want to describe adverse events and incidence associated with methadone when administered in combination with morphine or hydromorphone, specifically QTc prolongation that has been documented with study medication.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Group A: Control Arm (n = 30)", "type": "ACTIVE_COMPARATOR", "description": "Pt will receive: PCA opioid will include morphine OR hydromorphone (if patient has a sensitivity or is unable to tolerate or allergic to morphine). This is the exclusive medication/opioid in this arm. The starting doses will be as follows:\n\n* Starting dose for basal infusion of morphine is 0.02 mg/kg/hour up to a maximum of 50 kg.\n* Starting PCA dose for morphine is 0.02 mg/kg every 15 minutes for a lockout of 0.1 mg/kg up to a maximum of 50 kg or ideal body weight (PCA starting dose should be no more than 1 mg/push and no more than 5 mg/hour lockout).\n* Starting dose for basal infusion of hydromorphone is 0.003 mg/kg/hour up to a maximum of 50 kg IBW.\n* Starting PCA dose for hydromorphone is 0.003 mg/kg every 15 minutes for an hourly maximum lockout of 0.012 mg/kg up to a maximum of 50 kg (PCA start\n* PCA medications may be titrated up or down by 20-50% each day for desired analgesic effect with improved pain score, continue to engraftment or when medicine is no longer needed.", "intervention_names": ["Drug: PCA Alone (SOC)"]}, {"label": "Group B: Study or Experimental Arm (n = 30)", "type": "EXPERIMENTAL", "description": "The second arm will be methadone therapy that is scheduled to be given every 8 hours in addition to an on demand PCA. On demand PCA dosing will be the same as control arm but with NO basal/continuous rate. Intravenous methadone will be replacing basal infusion and serve as basal drug in place of continuous medication.\n\n* Starting dose for intravenous methadone is 0.1 mg/kg IV Q8hr up to a maximum of 50 kg. Singular starting methadone will be maximum of 5 mg.\n* Methadone may be increased by 20-50% every 48 hours due to half-life of medication. Reduction in analgesia will need to be monitored daily following a change. However, additional methadone increase should not occur until 48 hours have passed to allow for steady state of new dose to take effect. Reduction of methadone dosing by 20-50% can be made anytime per discretion of provider or if concerned about an adverse effect from the methadone.\n\nThis will continue until engraftment or until medicine is no longer needed.", "intervention_names": ["Drug: PCA plus methadone (Experimental)"]}], "interventions": [{"type": "DRUG", "name": "PCA plus methadone (Experimental)", "description": "This study is novel. There are no other interventions to distinguish in this or another study.", "arm_group_labels": ["Group B: Study or Experimental Arm (n = 30)"]}, {"type": "DRUG", "name": "PCA Alone (SOC)", "description": "PCA Alone (Control) arm. PCA opioid will include morphine OR hydromorphone (if patient has a sensitivity or is unable to tolerate or allergic to morphine).", "arm_group_labels": ["Group A: Control Arm (n = 30)"]}]}}, "company_search_urls": ["https://www.google.com/search?q=University of Texas Southwestern Medical Center+NCT06940570+terminated", "https://www.google.com/search?q=University of Texas Southwestern Medical Center+PCA Alone (SOC)+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": false, "search_query": "FDA warning letters or clinical holds for PCA Alone (SOC) by University of Texas Southwestern Medical Center. Include specific dates, reasons, and safety issues cited.", "error": "API error: 400"}, "sec_filings": {"found": false, "search_query": "SEC EDGAR 8-K filings by University of Texas Southwestern Medical Center mentioning clinical trial NCT06940570 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "search_params": {"company": "University of Texas Southwestern Medical Center", "nct_id": "NCT06940570", "start_date": "2028-01-01"}, "error": "API error: 400"}, "company_disclosures": {"found": false, "search_query": "Company press releases, investor presentations, or public statements by University of Texas Southwestern Medical Center about clinical trial NCT06940570 for PCA Alone (SOC). Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "search_params": {"company": "University of Texas Southwestern Medical Center", "nct_id": "NCT06940570", "drug_name": "PCA Alone (SOC)"}, "error": "API error: 400"}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason provided for the suspension of the trial is \"Study is closed with the IRB due to no funding. May resume once funding is obtained.\" This indicates that the trial was suspended due to administrative reasons, specifically a lack of funding, rather than safety or efficacy concerns.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T00:46:52.320669", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1106}}, "17": {"nct_id": "NCT06940570", "drug_name": "PCA plus methadone (Experimental)", "intervention_type": "DRUG", "drug_description": "This study is novel. There are no other interventions to distinguish in this or another study.", "phase": "PHASE3", "overall_status": "SUSPENDED", "why_stopped": "Study is closed with the IRB due to no funding. May resume once funding is obtained.", "title": "Methadone as an Alternative Treatment for Children Underdoing HSCT", "start_date": "2028-01-01", "completion_date": "2029-08-01", "sponsor": "University of Texas Southwestern Medical Center", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.749804", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T00:46:52.325401", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL651", "pref_name": "METHADONE", "targets": [{"chembl_id": "CHEMBL233", "ic50_values": [{"value": 4.1, "units": "nM"}], "uniprot_id": "B0FXJ1"}, {"chembl_id": "CHEMBL237", "ic50_values": [{"value": 512.0, "units": "nM"}], "uniprot_id": "E5RHC9"}, {"chembl_id": "CHEMBL236", "ic50_values": [{"value": 1090.0, "units": "nM"}], "uniprot_id": "B5B0B8"}, {"chembl_id": "CHEMBL240", "ic50_values": [{"value": 9772.37, "units": "nM"}], "uniprot_id": "A5H1P7"}, {"chembl_id": "CHEMBL612545", "ic50_values": [{"value": 23000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4302", "ic50_values": [{"value": 7500.0, "units": "nM"}], "uniprot_id": "A8K294"}, {"chembl_id": "CHEMBL2095229", "ic50_values": [{"value": 37400.0, "units": "nM"}], "uniprot_id": "B2RUT3"}, {"chembl_id": "CHEMBL4303835", "ic50_values": [{"value": 25100.0, "units": "nM"}, {"value": 25118.86, "units": "nM"}, {"value": 25100.0, "units": "nM"}, {"value": 25118.86, "units": "nM"}], "uniprot_id": null}], "has_uniprot_targets": true, "search_name": "PCA plus methadone (Experimental)"}, "ppi_enrichment": {"uniprot_count": 6, "interactions": [{"protein_a": "OPRD1", "protein_b": "POMC", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "OPRM1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PDYN", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PENK", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "OPRM1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "GRK5", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "OPRM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "ARRB1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "ARRB2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "OPRM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "ARRB2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "ARRB1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PENK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PDYN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "OPRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "ARRB1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "ARRB2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PDYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PENK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "PDYN", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GPRASP1", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PNOC", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI3", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "KNG1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "POMC", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "OPRM1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PDYN", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PENK", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "PENK", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "POMC", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "OPRM1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "GNAI1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "PDYN", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "OPRM1", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "OPRM1", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "KNG1", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PENK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PDYN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "OPRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GPRASP1", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PDYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PENK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "KNG1", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "PDYN", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PDYN", "protein_b": "KNG1", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "CACNA1C", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "SCN5A", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNH2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNJ2", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "CACNA1C", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNE2", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNE1", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "SCN5A", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNH2", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "HSPA4", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNH6", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "CACNA1C", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE3", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "HSP90AA1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "SCN5A", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE3", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE1", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "KCNE2", "protein_b": "KCNE3", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "KCNE2", "protein_b": "SCN5A", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNE3", "protein_b": "SCN5A", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "KCNE3", "protein_b": "KCNE1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "SCN5A", "protein_b": "KCNE1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "ABCF2", "protein_b": "ABCB1", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "SLCO1B1", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "NR1I2", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "ABCB1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "PPIG", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP3A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2C19", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "PPIG", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "CYP2C19", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCB1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "CYP3A4", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "NR1I2", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "ABCB1", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP2C19", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP3A4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "CYP3A4", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCB1", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "ABCF2-2", "protein_b": "ABCB1", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "CYP2C19", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "ABCB1", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "CYP3A4", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "ABCB1", "combined_score": 0.858, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "ABCB1", "protein_b": "CYP3A4", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "ABCB1", "protein_b": "IGKV2D-29", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA2D4", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNB1", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNB3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA2D1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CALML3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CALML6", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CALML5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CALM3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CALML4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CACNB3", "protein_b": "CACNB1", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNB3", "protein_b": "CACNB2", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CACNB3", "protein_b": "CACNA2D4", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CACNB3", "protein_b": "CACNA2D1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML4", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML3", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML5", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML4", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML5", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CACNB2", "protein_b": "CACNB1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CACNB2", "protein_b": "CACNA2D4", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CACNB2", "protein_b": "CACNA2D1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CACNA2D1", "protein_b": "CACNA2D4", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CACNA2D1", "protein_b": "CACNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "CALML4", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CACNA2D4", "protein_b": "CACNB1", "combined_score": 0.93, "interaction_type": "physical"}], "network_features": {"avg_degree": 6.0, "clustering_coefficient": 3.0}}, "failure_enrichment": {"aact_description": "Given high reports of pain while despite receiving PCA during transplant, our current management of mucositis induced pain is suboptimal. In a study of children receiving transplantation, pain was a main concern for this cohort during and after transplantation. The investigators propose to conduct this study to determine if methadone used as a primary analgesic in patients with mucositis can improve the current standard of care which will be demonstrated by improved pain scores, maintenance of functionality, and recovery during and following HSCT. This study will be a single blind randomized controlled design. Patients will be randomly assigned by permuted block randomization in groups of eight. Patient will be randomly assigned to receive either basal/PCA of one opioid (control) in the first arm OR PCA plus methadone where methadone will be used as basal long-acting medication (experimental).\n\nStudy subjects will be children who are undergoing an autologous or allogeneic stem cell transplant receiving a myeloablative regimen and meet all inclusion criteria. This unique population is being studied as it is a controlled setting where the PI can anticipate pain in \\>90% of the patients following ablation, the number of patients who experience mucositis after receiving ablative conditioning. The study will only be conducted in the inpatient stem cell transplant setting and no follow up should be necessary when these subjects are discharged from the hospital after transplant.\n\nThe following goals of the study are as follows:\n\n1. Will the concomitant administration of intravenous administered methadone with on demand opioid PCA improve pain score numbers in the PCA/methadone arm (experimental) in comparison to a continuous infusion PCA with demand opioid arm (control, standard of care)?\n2. Will the administration of methadone with increased individualized titration result in a reduction of 25% in total morphine milligram equivalents (MME) in experimental versus control arm?\n3. Will the methadone experimental arm increase functionality during transplantation period?\n4. Will those receiving methadone have reduced TPN days during hospital stay as compared to control arm?\n5. Will the child resumes oral intake more rapidly compared to control arm?\n6. The investigators also want to describe adverse events and incidence associated with methadone when administered in combination with morphine or hydromorphone, specifically QTc prolongation that has been documented with study medication.", "aact_documents": [], "pubmed_results": [{"pmid": "22834921", "title": "The perioperative combination of methadone and ketamine reduces post-operative opioid usage compared with methadone alone.", "authors": [{"name": "Pacreu S", "authtype": "Author", "clusterid": ""}, {"name": "Fern\u00e1ndez Candil J", "authtype": "Author", "clusterid": ""}, {"name": "Molt\u00f3 L", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "Mucositis is a normal side effect of stem cell transplant which happens as a result of chemotherapy being given prior to a new donor cell infusion (bone marrow transplant). The chemotherapy will kill cancer cells, but good cells, such as those in the mouth, are killed too. The mouth cells going away causes the areas in the mouth to be blistered, irritated, sore, and extremely painful. Pain medication (usually morphine or hydromorphone if allergic to morphine) are given when oral blisters are seen or felt by patient in patient's mouth. However, one pain medication given through a vein in the patient may or may not be effective and providers are often challenged with providing good pain control while waiting for the new donor cells to grow, which will then heal the mouth. This is a period of waiting that is 6-8 weeks.\n\nThe investigators know that methadone, a second pain medication, may decrease pain in a different way than morphine. This is because methadone works in a different way in the brain than morphine. By giving these pain medicines together, the hope of the study is to show decreased pain while waiting for new cells to grow.\n\nThe goal of this clinical trial is to hope to learn whether adding methadone (second pain medication) to the current pain medication which is morphine alone (all patients will receive this pain medication) will help reduce the pain experience of participant. Current treatment of morphine alone is sometimes not entirely effective and so any improvement of pain while waiting for new cells to grow is one of the goals of this study. If methadone is effective in decreasing pain, then patients may benefit in the future from using these two medications up front when getting a transplant.\n\nParticipant in this study between 6-18 years of age and is needing a stem cell transplant for a disease that can potentially be cured by transplantation.\n\nParticipant in this study is receiving chemotherapy and/or radiation conditioning that can cause mucositis. Participants are being asked to participate in this study because participants meet criteria to receive methadone that may or may not reduce pain experience versus just being given morphine alone, which is what all patients are given when the participants have mucositis.\n\nThe main goal of the study is to see if less opioid (pain medication) when methadone is added in comparison to participant who uses PCA only. The investigators also want to learn if patient's overall function is improved if given methadone. Another goal would be to see the number of TPN days the participant received and if the participant who was given methadone began to eat sooner. Other smaller goals include learning about side effects of methadone, and if the hospital stay is less for those who receive the study medication.\n\nThis medication will be given at Children's Medical Center of Dallas while participant is admitted for the stem cell transplant. There is no sponsor that is funding the study and this drug will be given free of charge in exchange for participation in the study", "detailed_description": "Given high reports of pain while despite receiving PCA during transplant, our current management of mucositis induced pain is suboptimal. In a study of children receiving transplantation, pain was a main concern for this cohort during and after transplantation. The investigators propose to conduct this study to determine if methadone used as a primary analgesic in patients with mucositis can improve the current standard of care which will be demonstrated by improved pain scores, maintenance of functionality, and recovery during and following HSCT. This study will be a single blind randomized controlled design. Patients will be randomly assigned by permuted block randomization in groups of eight. Patient will be randomly assigned to receive either basal/PCA of one opioid (control) in the first arm OR PCA plus methadone where methadone will be used as basal long-acting medication (experimental).\n\nStudy subjects will be children who are undergoing an autologous or allogeneic stem cell transplant receiving a myeloablative regimen and meet all inclusion criteria. This unique population is being studied as it is a controlled setting where the PI can anticipate pain in \\>90% of the patients following ablation, the number of patients who experience mucositis after receiving ablative conditioning. The study will only be conducted in the inpatient stem cell transplant setting and no follow up should be necessary when these subjects are discharged from the hospital after transplant.\n\nThe following goals of the study are as follows:\n\n1. Will the concomitant administration of intravenous administered methadone with on demand opioid PCA improve pain score numbers in the PCA/methadone arm (experimental) in comparison to a continuous infusion PCA with demand opioid arm (control, standard of care)?\n2. Will the administration of methadone with increased individualized titration result in a reduction of 25% in total morphine milligram equivalents (MME) in experimental versus control arm?\n3. Will the methadone experimental arm increase functionality during transplantation period?\n4. Will those receiving methadone have reduced TPN days during hospital stay as compared to control arm?\n5. Will the child resumes oral intake more rapidly compared to control arm?\n6. The investigators also want to describe adverse events and incidence associated with methadone when administered in combination with morphine or hydromorphone, specifically QTc prolongation that has been documented with study medication.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Group A: Control Arm (n = 30)", "type": "ACTIVE_COMPARATOR", "description": "Pt will receive: PCA opioid will include morphine OR hydromorphone (if patient has a sensitivity or is unable to tolerate or allergic to morphine). This is the exclusive medication/opioid in this arm. The starting doses will be as follows:\n\n* Starting dose for basal infusion of morphine is 0.02 mg/kg/hour up to a maximum of 50 kg.\n* Starting PCA dose for morphine is 0.02 mg/kg every 15 minutes for a lockout of 0.1 mg/kg up to a maximum of 50 kg or ideal body weight (PCA starting dose should be no more than 1 mg/push and no more than 5 mg/hour lockout).\n* Starting dose for basal infusion of hydromorphone is 0.003 mg/kg/hour up to a maximum of 50 kg IBW.\n* Starting PCA dose for hydromorphone is 0.003 mg/kg every 15 minutes for an hourly maximum lockout of 0.012 mg/kg up to a maximum of 50 kg (PCA start\n* PCA medications may be titrated up or down by 20-50% each day for desired analgesic effect with improved pain score, continue to engraftment or when medicine is no longer needed.", "intervention_names": ["Drug: PCA Alone (SOC)"]}, {"label": "Group B: Study or Experimental Arm (n = 30)", "type": "EXPERIMENTAL", "description": "The second arm will be methadone therapy that is scheduled to be given every 8 hours in addition to an on demand PCA. On demand PCA dosing will be the same as control arm but with NO basal/continuous rate. Intravenous methadone will be replacing basal infusion and serve as basal drug in place of continuous medication.\n\n* Starting dose for intravenous methadone is 0.1 mg/kg IV Q8hr up to a maximum of 50 kg. Singular starting methadone will be maximum of 5 mg.\n* Methadone may be increased by 20-50% every 48 hours due to half-life of medication. Reduction in analgesia will need to be monitored daily following a change. However, additional methadone increase should not occur until 48 hours have passed to allow for steady state of new dose to take effect. Reduction of methadone dosing by 20-50% can be made anytime per discretion of provider or if concerned about an adverse effect from the methadone.\n\nThis will continue until engraftment or until medicine is no longer needed.", "intervention_names": ["Drug: PCA plus methadone (Experimental)"]}], "interventions": [{"type": "DRUG", "name": "PCA plus methadone (Experimental)", "description": "This study is novel. There are no other interventions to distinguish in this or another study.", "arm_group_labels": ["Group B: Study or Experimental Arm (n = 30)"]}, {"type": "DRUG", "name": "PCA Alone (SOC)", "description": "PCA Alone (Control) arm. PCA opioid will include morphine OR hydromorphone (if patient has a sensitivity or is unable to tolerate or allergic to morphine).", "arm_group_labels": ["Group A: Control Arm (n = 30)"]}]}}, "company_search_urls": ["https://www.google.com/search?q=University of Texas Southwestern Medical Center+NCT06940570+terminated", "https://www.google.com/search?q=University of Texas Southwestern Medical Center+PCA plus methadone (Experimental)+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": false, "search_query": "FDA warning letters or clinical holds for PCA plus methadone (Experimental) by University of Texas Southwestern Medical Center. Include specific dates, reasons, and safety issues cited.", "error": "API error: 400"}, "sec_filings": {"found": false, "search_query": "SEC EDGAR 8-K filings by University of Texas Southwestern Medical Center mentioning clinical trial NCT06940570 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "search_params": {"company": "University of Texas Southwestern Medical Center", "nct_id": "NCT06940570", "start_date": "2028-01-01"}, "error": "API error: 400"}, "company_disclosures": {"found": false, "search_query": "Company press releases, investor presentations, or public statements by University of Texas Southwestern Medical Center about clinical trial NCT06940570 for PCA plus methadone (Experimental). Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "search_params": {"company": "University of Texas Southwestern Medical Center", "nct_id": "NCT06940570", "drug_name": "PCA plus methadone (Experimental)"}, "error": "API error: 400"}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason provided for the suspension of the trial is \"Study is closed with the IRB due to no funding. May resume once funding is obtained.\" This indicates that the trial was suspended due to administrative reasons, specifically a lack of funding, rather than safety or efficacy concerns.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T00:46:52.320669", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1106}}, "18": {"nct_id": "NCT06752876", "drug_name": "CB-010", "intervention_type": "DRUG", "drug_description": "CB-010 allogeneic CAR-T cell therapy, Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion", "phase": "PHASE1", "overall_status": "WITHDRAWN", "why_stopped": "Sponsor Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs", "title": "CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)", "start_date": "2027-12-31", "completion_date": "2029-04-30", "sponsor": "Caribou Biosciences, Inc.", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.750415", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T00:46:55.307839", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1165603", "pref_name": "JASPLAKINOLIDE CB", "targets": [{"chembl_id": null, "uniprot_id": "Q7Z570", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "A6NCI8", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q3V0A6", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "CB-010", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 3, "interactions": [{"protein_a": "NRGN", "protein_b": "ZNF804A", "combined_score": 0.707, "interaction_type": "physical"}, {"protein_a": "ZNF804A", "protein_b": "COMT", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "ZNF804A", "protein_b": "DTNBP1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "ZNF804A", "protein_b": "DAOA", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "ZNF804A", "protein_b": "DISC1", "combined_score": 0.785, "interaction_type": "physical"}, {"protein_a": "DTNBP1", "protein_b": "COMT", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "DTNBP1", "protein_b": "DAOA", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "DTNBP1", "protein_b": "DISC1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DISC1", "combined_score": 0.715, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DAOA", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "DISC1", "protein_b": "DAOA", "combined_score": 0.821, "interaction_type": "physical"}], "network_features": {"avg_degree": 3.67, "clustering_coefficient": 1.83}}, "failure_enrichment": {"aact_description": "Participants enrolled can expect to be on the study for a total duration of approximately 2 years, during which there will be a screening period followed by a single administration of CB-010 and then 24 months of safety follow-up and monitoring.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a Phase 1 study to evaluate the safety and efficacy of a single infusion of CB-010 in patients with refractory Systemic Lupus Erythematosus (SLE) with cohorts for lupus nephritis (LN) and extrarenal lupus (ERL).", "detailed_description": "Participants enrolled can expect to be on the study for a total duration of approximately 2 years, during which there will be a screening period followed by a single administration of CB-010 and then 24 months of safety follow-up and monitoring.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Cohort 1 Lupus Nephritis (LN)", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: CB-010"]}, {"label": "Cohort 2 Extrarenal Lupus (ERL)", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: CB-010"]}], "interventions": [{"type": "DRUG", "name": "CB-010", "description": "CB-010 allogeneic CAR-T cell therapy, Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion", "arm_group_labels": ["Cohort 1 Lupus Nephritis (LN)", "Cohort 2 Extrarenal Lupus (ERL)"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Caribou Biosciences, Inc.+NCT06752876+terminated", "https://www.google.com/search?q=Caribou Biosciences, Inc.+CB-010+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": false, "search_query": "FDA warning letters or clinical holds for CB-010 by Caribou Biosciences, Inc.. Include specific dates, reasons, and safety issues cited.", "error": "API error: 400"}, "sec_filings": {"found": false, "search_query": "SEC EDGAR 8-K filings by Caribou Biosciences, Inc. mentioning clinical trial NCT06752876 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "search_params": {"company": "Caribou Biosciences, Inc.", "nct_id": "NCT06752876", "start_date": "2027-12-31"}, "error": "API error: 400"}, "company_disclosures": {"found": false, "search_query": "Company press releases, investor presentations, or public statements by Caribou Biosciences, Inc. about clinical trial NCT06752876 for CB-010. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "search_params": {"company": "Caribou Biosciences, Inc.", "nct_id": "NCT06752876", "drug_name": "CB-010"}, "error": "API error: 400"}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal is \"Sponsor Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs.\" This indicates that the trial was terminated due to administrative and strategic decisions by the sponsor, rather than safety or efficacy concerns. The trial was withdrawn, not suspended or terminated, further suggesting an administrative reason rather than failure to meet safety or efficacy endpoints.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T00:46:55.307404", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1146}}, "25": {"nct_id": "NCT05452408", "drug_name": "Antitumor B KAC", "intervention_type": "DRUG", "drug_description": "ATB-KAC will be administered at a dose of 720 mg three times per day (roughly spaced every eight hours) as has been studied for ATB-KAC in human oral leukoplakia trials and in esophageal cancer prevention trials. ATB-KAC may be taken with or without food.", "phase": "PHASE1", "overall_status": "WITHDRAWN", "why_stopped": "Study abandoned.", "title": "Antitumor-B KAC PK Study", "start_date": "2026-12-31", "completion_date": "2027-12-31", "sponsor": "Medical College of Wisconsin", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.753082", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T00:46:57.962733", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1160385", "pref_name": "GUANACLINE", "targets": [], "has_uniprot_targets": false, "search_name": "Antitumor B KAC"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "Study Rationale: Establishing the PK profile for antitumor B key active components (ATB-KAC) is a critical initial step before future clinical trials can be performed that examine anticancer and cancer preventive effects of ATB-KAC.\n\nStudy Intervention Description: Study participants will take the natural botanical compound ATB-KAC during a short window (seven to 28 days). Participants will provide blood samples and saliva samples during ATB-KAC administration and a portion of the initial tumor biopsy.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "Study Design: A Window of Opportunity Clinical Trial. This study design permits examination of effects of an oral agent on cancer patients during the \"window\" between diagnosis of their cancer and their definitive cancer surgery. Similar to a phase 0 study, the trial design permits examination of the biologic effects of an agent; in this study pharmacokinetic properties will be examined.", "detailed_description": "Study Rationale: Establishing the PK profile for antitumor B key active components (ATB-KAC) is a critical initial step before future clinical trials can be performed that examine anticancer and cancer preventive effects of ATB-KAC.\n\nStudy Intervention Description: Study participants will take the natural botanical compound ATB-KAC during a short window (seven to 28 days). Participants will provide blood samples and saliva samples during ATB-KAC administration and a portion of the initial tumor biopsy.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Antitumor B KAC", "type": "EXPERIMENTAL", "description": "ATB will be administered on an outpatient basis.", "intervention_names": ["Drug: Antitumor B KAC"]}], "interventions": [{"type": "DRUG", "name": "Antitumor B KAC", "description": "ATB-KAC will be administered at a dose of 720 mg three times per day (roughly spaced every eight hours) as has been studied for ATB-KAC in human oral leukoplakia trials and in esophageal cancer prevention trials. ATB-KAC may be taken with or without food.", "arm_group_labels": ["Antitumor B KAC"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Medical College of Wisconsin+NCT05452408+terminated", "https://www.google.com/search?q=Medical College of Wisconsin+Antitumor B KAC+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": false, "search_query": "FDA warning letters or clinical holds for Antitumor B KAC by Medical College of Wisconsin. Include specific dates, reasons, and safety issues cited.", "error": "API error: 400"}, "sec_filings": {"found": false, "search_query": "SEC EDGAR 8-K filings by Medical College of Wisconsin mentioning clinical trial NCT05452408 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "search_params": {"company": "Medical College of Wisconsin", "nct_id": "NCT05452408", "start_date": "2026-12-31"}, "error": "API error: 400"}, "company_disclosures": {"found": false, "search_query": "Company press releases, investor presentations, or public statements by Medical College of Wisconsin about clinical trial NCT05452408 for Antitumor B KAC. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "search_params": {"company": "Medical College of Wisconsin", "nct_id": "NCT05452408", "drug_name": "Antitumor B KAC"}, "error": "API error: 400"}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal is \"Study abandoned,\" which indicates an administrative or operational issue rather than a failure due to safety or efficacy concerns. The detailed description does not mention any safety or efficacy issues, but rather focuses on the study's rationale and intervention. The lack of any PubMed publications also suggests that the trial was terminated before reaching a point where results could be published, further supporting an administrative reason for the withdrawal.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T00:46:57.962299", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1117}}, "35": {"nct_id": "NCT04585711", "drug_name": "Etanercept Optimal dosing", "intervention_type": "DRUG", "drug_description": "Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.", "phase": "PHASE1", "overall_status": "WITHDRAWN", "why_stopped": "Funding expired", "title": "Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis", "start_date": "2026-07-01", "completion_date": "2027-02-28", "sponsor": "Duke University", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.756054", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T00:47:00.309548", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1201572", "pref_name": "ETANERCEPT", "targets": [], "has_uniprot_targets": false, "search_name": "Etanercept Optimal dosing"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "PRECISE is an open-label, single arm, single-center site study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of dosing interval-optimized etanercept in obese patients with Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA). Approximately 30 patients with JIA or RA who are starting etanercept standard-of-care will take part in the study.\n\nEligible patients will have blood collections before and after starting the biologic of interest to assess PK and disease activity. Five (5) blood samples will be collected through a combination of clinic and home visits.", "aact_documents": [], "pubmed_results": [{"pmid": "39177653", "title": "Perispinal etanercept stroke trial design: PESTO and beyond.", "authors": [{"name": "Tobinick E", "authtype": "Author", "clusterid": ""}, {"name": "Ucci D", "authtype": "Author", "clusterid": ""}, {"name": "Bermudo K", "authtype": "Author", "clusterid": ""}]}, {"pmid": "36443174", "title": "A randomized controlled pilot trial of etanercept and alpha-1 antitrypsin to improve autologous islet engraftment.", "authors": [{"name": "Abdel-Karim TR", "authtype": "Author", "clusterid": ""}, {"name": "Hodges JS", "authtype": "Author", "clusterid": ""}, {"name": "Pruett TL", "authtype": "Author", "clusterid": ""}]}, {"pmid": "36315419", "title": "Reduced prescription of TNF-inhibitors in chronic arthritis based on therapeutic drug monitoring: A randomized controlled trial.", "authors": [{"name": "Pfeiffer-Jensen M", "authtype": "Author", "clusterid": ""}, {"name": "Liao D", "authtype": "Author", "clusterid": ""}, {"name": "Tarp U", "authtype": "Author", "clusterid": ""}]}, {"pmid": "32735145", "title": "Radiographic and clinical effects of 10\u2009mg and 25\u2009mg twice-weekly etanercept over 52 weeks in Japanese patients with active rheumatoid arthritis.", "authors": [{"name": "Takeuchi T", "authtype": "Author", "clusterid": ""}, {"name": "Miyasaka N", "authtype": "Author", "clusterid": ""}, {"name": "Pedersen RD", "authtype": "Author", "clusterid": ""}]}, {"pmid": "28968858", "title": "Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?", "authors": [{"name": "Ibrahim F", "authtype": "Author", "clusterid": ""}, {"name": "Lorente-C\u00e1novas B", "authtype": "Author", "clusterid": ""}, {"name": "Dor\u00e9 CJ", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "The purpose of this study is to learn more about how adult and children's bodies use etanercept and how bodyweight influences how well etanercept works. This study will help us understand the proper dose of etanercept in obese children and adults.", "detailed_description": "PRECISE is an open-label, single arm, single-center site study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of dosing interval-optimized etanercept in obese patients with Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA). Approximately 30 patients with JIA or RA who are starting etanercept standard-of-care will take part in the study.\n\nEligible patients will have blood collections before and after starting the biologic of interest to assess PK and disease activity. Five (5) blood samples will be collected through a combination of clinic and home visits.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Optimal dosing", "type": "OTHER", "description": "Obese children (\u2265 2 year old) and adults with juvenile idiopathic arthritis (JIA) or Rheumatoid Arthritis (RA) who are starting etanercept as part of their routine medical care.", "intervention_names": ["Drug: Etanercept Optimal dosing"]}], "interventions": [{"type": "DRUG", "name": "Etanercept Optimal dosing", "description": "Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.", "arm_group_labels": ["Optimal dosing"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Duke University+NCT04585711+terminated", "https://www.google.com/search?q=Duke University+Etanercept Optimal dosing+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": false, "search_query": "FDA warning letters or clinical holds for Etanercept Optimal dosing by Duke University. Include specific dates, reasons, and safety issues cited.", "error": "API error: 400"}, "sec_filings": {"found": false, "search_query": "SEC EDGAR 8-K filings by Duke University mentioning clinical trial NCT04585711 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "search_params": {"company": "Duke University", "nct_id": "NCT04585711", "start_date": "2026-07-01"}, "error": "API error: 400"}, "company_disclosures": {"found": false, "search_query": "Company press releases, investor presentations, or public statements by Duke University about clinical trial NCT04585711 for Etanercept Optimal dosing. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "search_params": {"company": "Duke University", "nct_id": "NCT04585711", "drug_name": "Etanercept Optimal dosing"}, "error": "API error: 400"}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The trial was reported as \"WITHDRAWN\" due to the official reason of \"Funding expired.\" This indicates that the trial was terminated due to administrative and operational issues, rather than safety or efficacy concerns. The detailed description does not mention any safety or efficacy issues that led to the termination of the trial.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T00:47:00.309090", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1113}}, "45": {"nct_id": "NCT05683574", "drug_name": "cyclobenzaprine hydrochloride + etoricoxib placebo", "intervention_type": "DRUG", "drug_description": "Participants randomized to this group will receive one (01) cyclobenzaprine hydrochloride 15 mg capsule (XL - Mitrul\u00ae) and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.", "phase": "PHASE3", "overall_status": "WITHDRAWN", "why_stopped": "Change in study strategy.", "title": "Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil", "start_date": "2026-05-30", "completion_date": "2028-02-28", "sponsor": "Eurofarma Laboratorios S.A.", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.759328", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T00:47:03.269616", "retry_count": 0}, "failure_enrichment": {"aact_description": "The investigational drug consists of a fixed-dose combination (FDC) that contains etoricoxib, a non-steroidal anti-inflammatory drug (NSAID) with analgesic action, and cyclobenzaprine hydrochloride, a myorelaxant, in doses of 90 mg and 15 mg, respectively, in the dosage form of a prolonged-release hard capsule. This product is an unprecedented FDC in the country, and is indicated for the short-term treatment of moderate to serious acute pain associated with muscle spasm. Pain management with analgesic drugs, such as NSAIDs and other adjuvant drugs, is common in daily clinical practice. In parallel with its additive effect on pain relief, the FDC of an anti-inflammatory and myorelaxant agent seeks to assist in greater control of associated musculoskeletal symptoms, such as inflammatory processes, limited range of motion, and muscle spasms.\n\nMulticenter, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Comparative Superiority clinical trial. Patients aged between 18 and 35 years with indication for surgical removal of an impacted lower third molar and an antagonistic upper third molar will be randomized in a 1:1:1 ratio to receive the FDC of etoricoxib 90 mg + cyclobenzaprine hydrochloride 15 mg from Eurofarma Laborat\u00f3rios SA (investigational drug), in capsules, or the mono-drugs etoricoxib 90 mg (Arcoxia\u00ae), in tablets, or cyclobenzaprine hydrochloride 15 mg (XL - Mitrul\u00ae), in capsules, for up to three (03) days. Participants whose surgery lasts a maximum of 80 minutes (counted from the initial incision to the extraction of the third molars) and who present moderate to serious postoperative pain up to a maximum of four (04) hours will be randomized. The first administration of study treatment will be made at the study center when post-surgical pain reaches moderate/serious intensity (\u2265 40 mm on visual analogue scale \\[VAS\\] 0-100 mm). The participants will be instructed, from then on, to use the study treatment, respecting a minimum interval of twenty-four (24) hours between doses taken for three (03) days.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "Etoricoxib and cyclobenzaprine hydrochloride are active pharmaceutical ingredients (APIs) already registered in the country as mono-drugs. These products are widely used for the proposed indications, and their safety and efficacy profiles are known in daily clinical practice. Once the absence of a pharmacokinetic interaction between etoricoxib and cyclobenzaprine hydrochloride has been confirmed in relative bioavailability studies, this phase 3 study will be conducted for demonstrating the superiority of the new FDC over etoricoxib 90 mg (Arcoxia\u00ae) and cyclobenzaprine hydrochloride 15 mg (XL - Mitrul\u00ae) in the treatment of moderate to serious pain associated with muscle spasm. The purpose is to provide a new, effective, and safe therapeutic option to address these cases. Etoricoxib and cyclobenzaprine hydrochloride are active pharmaceutical ingredients (APIs) already registered in the country as mono-drugs. These products are widely used for the proposed indications, and their safety and efficacy profiles are known in daily clinical practice. Once the absence of a pharmacokinetic interaction between etoricoxib and cyclobenzaprine hydrochloride has been confirmed in relative bioavailability studies, this phase 3 study will be conducted for demonstrating the superiority of the new FDC over etoricoxib 90 mg (Arcoxia\u00ae) and cyclobenzaprine hydrochloride 15 mg (XL - Mitrul\u00ae) in the treatment of moderate to serious pain associated with muscle spasm. The purpose is to provide a new, effective, and safe therapeutic option to address these cases.", "detailed_description": "The investigational drug consists of a fixed-dose combination (FDC) that contains etoricoxib, a non-steroidal anti-inflammatory drug (NSAID) with analgesic action, and cyclobenzaprine hydrochloride, a myorelaxant, in doses of 90 mg and 15 mg, respectively, in the dosage form of a prolonged-release hard capsule. This product is an unprecedented FDC in the country, and is indicated for the short-term treatment of moderate to serious acute pain associated with muscle spasm. Pain management with analgesic drugs, such as NSAIDs and other adjuvant drugs, is common in daily clinical practice. In parallel with its additive effect on pain relief, the FDC of an anti-inflammatory and myorelaxant agent seeks to assist in greater control of associated musculoskeletal symptoms, such as inflammatory processes, limited range of motion, and muscle spasms.\n\nMulticenter, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Comparative Superiority clinical trial. Patients aged between 18 and 35 years with indication for surgical removal of an impacted lower third molar and an antagonistic upper third molar will be randomized in a 1:1:1 ratio to receive the FDC of etoricoxib 90 mg + cyclobenzaprine hydrochloride 15 mg from Eurofarma Laborat\u00f3rios SA (investigational drug), in capsules, or the mono-drugs etoricoxib 90 mg (Arcoxia\u00ae), in tablets, or cyclobenzaprine hydrochloride 15 mg (XL - Mitrul\u00ae), in capsules, for up to three (03) days. Participants whose surgery lasts a maximum of 80 minutes (counted from the initial incision to the extraction of the third molars) and who present moderate to serious postoperative pain up to a maximum of four (04) hours will be randomized. The first administration of study treatment will be made at the study center when post-surgical pain reaches moderate/serious intensity (\u2265 40 mm on visual analogue scale \\[VAS\\] 0-100 mm). The participants will be instructed, from then on, to use the study treatment, respecting a minimum interval of twenty-four (24) hours between doses taken for three (03) days.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "etoricoxib 90 mg + cyclobenzaprine 15 mg", "type": "EXPERIMENTAL", "description": "Investigational group: FDC of etoricoxib 90 mg + cyclobenzaprine 15 mg from Eurofarma Laborat\u00f3rios SA", "intervention_names": ["Drug: FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo"]}, {"label": "etoricoxib 90 mg", "type": "ACTIVE_COMPARATOR", "description": "Comparator group: etoricoxib 90 mg (Arcoxia\u00ae)", "intervention_names": ["Drug: etoricoxib 90 mg (Arcoxia\u00ae) +FDC placebo"]}, {"label": "cyclobenzaprine hydrochloride 15 mg", "type": "ACTIVE_COMPARATOR", "description": "Comparator group: cyclobenzaprine hydrochloride 15 mg (XL - Mitrul\u00ae)", "intervention_names": ["Drug: cyclobenzaprine hydrochloride + etoricoxib placebo"]}], "interventions": [{"type": "DRUG", "name": "FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo", "description": "Participants randomized to this group will receive one (01) capsule of the investigational drug and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.", "arm_group_labels": ["etoricoxib 90 mg + cyclobenzaprine 15 mg"]}, {"type": "DRUG", "name": "etoricoxib 90 mg (Arcoxia\u00ae) +FDC placebo", "description": "Participants randomized to this group will receive one (01) etoricoxib 90 mg tablet (Arcoxia\u00ae) and one (01) FDC placebo capsule, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.", "arm_group_labels": ["etoricoxib 90 mg"]}, {"type": "DRUG", "name": "cyclobenzaprine hydrochloride + etoricoxib placebo", "description": "Participants randomized to this group will receive one (01) cyclobenzaprine hydrochloride 15 mg capsule (XL - Mitrul\u00ae) and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.", "arm_group_labels": ["cyclobenzaprine hydrochloride 15 mg"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Eurofarma Laboratorios S.A.+NCT05683574+terminated", "https://www.google.com/search?q=Eurofarma Laboratorios S.A.+cyclobenzaprine hydrochloride + etoricoxib placebo+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": false, "search_query": "FDA warning letters or clinical holds for cyclobenzaprine hydrochloride + etoricoxib placebo by Eurofarma Laboratorios S.A.. Include specific dates, reasons, and safety issues cited.", "error": "API error: 400"}, "sec_filings": {"found": false, "search_query": "SEC EDGAR 8-K filings by Eurofarma Laboratorios S.A. mentioning clinical trial NCT05683574 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "search_params": {"company": "Eurofarma Laboratorios S.A.", "nct_id": "NCT05683574", "start_date": "2026-05-30"}, "error": "API error: 400"}, "company_disclosures": {"found": false, "search_query": "Company press releases, investor presentations, or public statements by Eurofarma Laboratorios S.A. about clinical trial NCT05683574 for cyclobenzaprine hydrochloride + etoricoxib placebo. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "search_params": {"company": "Eurofarma Laboratorios S.A.", "nct_id": "NCT05683574", "drug_name": "cyclobenzaprine hydrochloride + etoricoxib placebo"}, "error": "API error: 400"}}}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1200636", "pref_name": "CYCLOBENZAPRINE HYDROCHLORIDE", "targets": [{"chembl_id": "CHEMBL364", "ic50_values": [{"value": 10000.0, "units": "nM"}, {"value": 5011.87, "units": "nM"}, {"value": 12589.25, "units": "nM"}, {"value": 12589.25, "units": "nM"}, {"value": 10000.0, "units": "nM"}, {"value": 5011.87, "units": "nM"}], "uniprot_id": null}], "has_uniprot_targets": false, "search_name": "cyclobenzaprine hydrochloride + etoricoxib placebo"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the withdrawal of this Phase 1 clinical trial is \"Change in study strategy.\" This indicates that the trial was terminated due to administrative or operational reasons, rather than due to safety concerns or lack of efficacy. The detailed description does not mention any safety issues or poor efficacy results that led to the termination of the trial. Therefore, based on the information provided, the most likely reason for the trial failure is administrative, such as a change in the sponsor's strategic priorities or operational challenges.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T00:47:03.268979", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1420}}}}